Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Cross-species comparison of the metabolism and excretion of selexipag.

Ichikawa T, Yamada T, Treiber A, Gnerre C, Segrestaa J, Seeland S, Nonaka K.

Xenobiotica. 2019 Mar;49(3):284-301. doi: 10.1080/00498254.2018.1444814. Epub 2018 Mar 21.

PMID:
29468921
2.

The metabolism and drug-drug interaction potential of the selective prostacyclin receptor agonist selexipag.

Gnerre C, Segrestaa J, Seeland S, Äänismaa P, Pfeifer T, Delahaye S, de Kanter R, Ichikawa T, Yamada T, Treiber A.

Xenobiotica. 2018 Jul;48(7):704-719. doi: 10.1080/00498254.2017.1357088. Epub 2017 Aug 30.

PMID:
28737453
3.

Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low β-Arrestin Recruitment and Desensitization Potential.

Gatfield J, Menyhart K, Wanner D, Gnerre C, Monnier L, Morrison K, Hess P, Iglarz M, Clozel M, Nayler O.

J Pharmacol Exp Ther. 2017 Jul;362(1):186-199. doi: 10.1124/jpet.116.239665. Epub 2017 May 5.

PMID:
28476928
4.

Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys.

Ichikawa T, Yamada T, Treiber A, Gnerre C, Nonaka K.

Xenobiotica. 2018 Feb;48(2):186-196. doi: 10.1080/00498254.2017.1294277. Epub 2017 Mar 2.

PMID:
28277164
5.

4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y12 Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel.

Caroff E, Hubler F, Meyer E, Renneberg D, Gnerre C, Treiber A, Rey M, Hess P, Steiner B, Hilpert K, Riederer MA.

J Med Chem. 2015 Dec 10;58(23):9133-53. doi: 10.1021/acs.jmedchem.5b00933. Epub 2015 Nov 18.

PMID:
26550844
6.

Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.

de Kanter R, Sidharta PN, Delahaye S, Gnerre C, Segrestaa J, Buchmann S, Kohl C, Treiber A.

Clin Pharmacokinet. 2016 Mar;55(3):369-80. doi: 10.1007/s40262-015-0322-y.

PMID:
26385839
7.

Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist.

Gehin M, Sidharta PN, Gnerre C, Treiber A, Halabi A, Dingemanse J.

Eur J Clin Pharmacol. 2015 Jan;71(1):15-23. doi: 10.1007/s00228-014-1767-x. Epub 2014 Oct 18.

PMID:
25323804
8.
9.

Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffold.

Valdenaire A, Pothier J, Renneberg D, Riederer MA, Peter O, Leroy X, Gnerre C, Fretz H.

Bioorg Med Chem Lett. 2013 Feb 15;23(4):944-8. doi: 10.1016/j.bmcl.2012.12.050. Epub 2012 Dec 25.

PMID:
23324405
10.

Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotype.

Pothier J, Riederer MA, Peter O, Leroy X, Valdenaire A, Gnerre C, Fretz H.

Bioorg Med Chem Lett. 2012 Jul 15;22(14):4660-4. doi: 10.1016/j.bmcl.2012.05.087. Epub 2012 Jun 1.

PMID:
22726929
11.

Regulation of human liver delta-aminolevulinic acid synthase by bile acids.

Peyer AK, Jung D, Beer M, Gnerre C, Keogh A, Stroka D, Zavolan M, Meyer UA.

Hepatology. 2007 Dec;46(6):1960-70.

PMID:
17975826
12.

Lipophilicity plays a major role in modulating the inhibition of monoamine oxidase B by 7-substituted coumarins.

Carotti A, Altomare C, Catto M, Gnerre C, Summo L, De Marco A, Rose S, Jenner P, Testa B.

Chem Biodivers. 2006 Feb;3(2):134-49.

PMID:
17193252
13.

LXR deficiency and cholesterol feeding affect the expression and phenobarbital-mediated induction of cytochromes P450 in mouse liver.

Gnerre C, Schuster GU, Roth A, Handschin C, Johansson L, Looser R, Parini P, Podvinec M, Robertsson K, Gustafsson JA, Meyer UA.

J Lipid Res. 2005 Aug;46(8):1633-42. Epub 2005 Jun 1.

14.

Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids.

Handschin C, Gnerre C, Fraser DJ, Martinez-Jimenez C, Jover R, Meyer UA.

Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.

PMID:
15629111
15.

The evolution of drug-activated nuclear receptors: one ancestral gene diverged into two xenosensor genes in mammals.

Handschin C, Blättler S, Roth A, Looser R, Oscarson M, Kaufmann MR, Podvinec M, Gnerre C, Meyer UA.

Nucl Recept. 2004 Oct 12;2(1):7.

16.

Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene.

Gnerre C, Blättler S, Kaufmann MR, Looser R, Meyer UA.

Pharmacogenetics. 2004 Oct;14(10):635-45.

PMID:
15454728
17.

Natural and synthetic geiparvarins are strong and selective MAO-B inhibitors. Synthesis and SAR studies.

Carotti A, Carrieri A, Chimichi S, Boccalini M, Cosimelli B, Gnerre C, Carotti A, Carrupt PA, Testa B.

Bioorg Med Chem Lett. 2002 Dec 16;12(24):3551-5.

PMID:
12443774
18.

Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor.

van Giersbergen PL, Gnerre C, Treiber A, Dingemanse J, Meyer UA.

Eur J Pharmacol. 2002 Aug 23;450(2):115-21.

PMID:
12206849
19.
20.
21.

Monoamine oxidase inhibitor properties of some benzazoles: structure-activity relationships.

Grandi T, Sparatore F, Gnerre C, Crivori P, Carrupt PA, Testa B.

AAPS PharmSci. 1999;1(4):E16.

22.

Monoamine oxidase inhibitory activity of some Hypericum species native to South Brazil.

Gnerre C, von Poser GL, Ferraz A, Viana A, Testa B, Rates SM.

J Pharm Pharmacol. 2001 Sep;53(9):1273-9.

PMID:
11578110
23.

Interaction of psychotropic drugs with monoamine oxidase in rat brain.

Gnerre C, Kosel M, Baumann P, Carrupt PA, Testa B.

J Pharm Pharmacol. 2001 Aug;53(8):1125-30.

PMID:
11518022
24.

Inhibition of monoamine oxidases by functionalized coumarin derivatives: biological activities, QSARs, and 3D-QSARs.

Gnerre C, Catto M, Leonetti F, Weber P, Carrupt PA, Altomare C, Carotti A, Testa B.

J Med Chem. 2000 Dec 14;43(25):4747-58.

PMID:
11123983

Supplemental Content

Loading ...
Support Center